New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
09:24 EDTMNKD, ARNAMannKind shares may fall after Afrezza approval, Feuerstein says
MannKind (MNKD) shares are likely to go higher into the July 15 FDA decision on Afrezza, but are likely to sell off following the drug's approval, The Street's Adam Feuerstein argues. Feuerstein lays out similarities between MannKind and Arena Pharmaceuticals (ARNA). Reference Link
News For MNKD;ARNA From The Last 14 Days
Check below for free stories on MNKD;ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
09:59 EDTARNAArena to need longer studies of 'Bel-phen' combo to judge safety, TheStreet says
Subscribe for More Information
September 11, 2014
12:42 EDTARNAOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTARNAArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTARNAOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 10, 2014
06:02 EDTMNKDMannKind implied volatility of 56 at lower end of index mean range
Subscribe for More Information
September 9, 2014
12:46 EDTARNANovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
06:04 EDTMNKDMannKind implied volatility of 56 at lower end of index mean range

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use